Illustrative comparative risks* (95% CI) | ||||||
---|---|---|---|---|---|---|
Assumed risk | Corresponding risk | |||||
Outcomes | Placebo or alternative treatment | Oral H1 antihistamines | Relative effect (95% CI) | No of participants (studies) | Quality of the evidence (GRADE) | Comments |
Reduction of subjectively perceived itch, as determined by validated rating scales | - | - | Not estimable | 0 (0) | No evidence from RCTs that met our inclusion criteria1 | No RCT could be included |
Global improvement in eczema, as measured by reduction in an eczema severity score such as SCORAD | - | - | Not estimable | 0 (0) | No evidence from RCTs that met our inclusion criteria1 | No RCT could be included |
Percentage of participants reporting adverse effects/adverse events | - | - | Not estimable | 0 (0) | No evidence from RCTs that met our inclusion criteria1 | No RCT could be included |
Improvement in quality of life measures | - | - | Not estimable | 0 (0) | No evidence from RCTs that met our inclusion criteria1 | No RCT could be included |